文献速递泌尿男性生殖肿瘤

高危局限期前列腺癌的中度大分割放疗:一项III期随机试验的最终结果

Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
PubMed 文献 · J Clin Oncol · 2017-03-29

这项单机构随机试验于2003年1月至2007年12月入组168例高危局限期前列腺癌患者,1:1随机接受常规放疗(80 Gy/40次/8周)或大分割放疗(62 Gy/20次/5周)至前列腺及精囊。中位随访9年,两组≥2级晚期胃肠和泌尿生殖毒性无差异,10年FFBF、OS、PCaSS均无显著差异;多因素分析中大分割是FFBF和PCaSS的显著预后因素。

要点

  • 168例高危局限期前列腺癌随机接受常规80 Gy/40次或大分割62 Gy/20次放疗。
  • 中位随访9年,两组≥2级晚期胃肠毒性(P=.68)和泌尿生殖毒性(P=.57)无差异。
  • 10年FFBF大分割组72% vs 常规组65%(P=.148),OS 75% vs 64%(P=.22),PCaSS 95% vs 88%(P=.066)。

核心结论

  • 长期结果显示大分割放疗未能实现减少医生评估的晚期毒性或保持同等疗效的意图。
  • 随机化后分析显示,校正临床预后变量后,大分割是FFBF和PCaSS的显著预后因素。

研究设计与样本

  • 单机构随机临床试验,2003年1月至2007年12月入组168例高危局限期前列腺癌患者,1:1随机分配。
  • 常规放疗组85例接受80 Gy/40次/8周,大分割放疗组83例接受62 Gy/20次/5周,均照射前列腺及精囊。
  • 主要终点为晚期毒性,次要终点包括无生化失败生存(FFBF)、前列腺癌特异性生存(PCaSS)和总生存(OS),按意向性治疗分析。

主要发现

  • 中位随访9年(四分位距7.5至10.1年),医生评估的≥2级晚期胃肠毒性两组无差异(P=.68),≥2级晚期泌尿生殖毒性两组无差异(P=.57)。
  • 10年FFBF率大分割组72% vs 常规组65%(P=.148)。
  • 10年OS率大分割组75% vs 常规组64%(P=.22)。
  • 10年PCaSS率大分割组95% vs 常规组88%(P=.066)。
  • 多因素分析中,FFBF的显著预后变量为大分割、治疗前前列腺特异性抗原水平、Gleason评分和临床肿瘤分期;PCaSS的显著预后变量为大分割和Gleason评分。

关键数值与推荐

  • 常规放疗方案:80 Gy分40次,8周完成。
  • 大分割放疗方案:62 Gy分20次,5周完成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To report the final results on treatment outcomes of a randomized trial comparing conventional and hypofractionated radiotherapy in high-risk, organ-confined prostate cancer (PCa). Patients and Methods This single-institution, randomized clinical trial, conducted from January 2003 to December 2007, enrolled 168 patients with high-risk PCa who were randomly assigned in a 1:1 ratio to conventional (80 Gy in 40 fractions in 8 weeks) or hypofractionated radiotherapy (62 Gy in 20 fractions in 5 weeks) to prostate and seminal vesicles. The primary outcome measure was late toxicity. Additional outcomes were freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCaSS), and overall survival (OS), evaluated on an intention-to-treat basis. Results A total of 85 patients were assigned to conventional and 83 to hypofractionated radiotherapy. At a median follow-up of 9 years (interquartile range, 7.5 to 10.1 years), no differences was observed in physician-assessed late gastro intestinal and genitourinary toxicity greater than or equal to grade 2 ( P = .68 and .57, respectively) were found between the two arms. The 10-year FFBF rate was 72% in the hypofractionation group and 65% in the conventional fractionation group ( P = .148). Ten-year OS rates were 75% in the hypofractionation group and 64% in the conventional group, respectively ( P = .22). The same features for 10-year PCaSS were 95% and 88%, respectively ( P = .066). Hypofractionation, pretreatment prostate-specific antigen level, Gleason score, and clinical tumor stage for FFBF, and hypofractionation and Gleason score for PCaSS were significant prognostic variables on the multivariate analysis. Conclusion Long-term findings showed that hypofractionated radiotherapy failed the intent of either reducing physician-assessed late toxicity or maintaining the same efficacy. A postrandomization analysis, however, revealed that hypofractionation was a significant prognostic factor for FFBF and PCaSS, when adjusted for clinical prognostic variables.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Arcangeli G, Saracino B, Arcangeli S, et al. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. J Clin Oncol. 2017. PMID: 28355113. doi:10.1200/JCO.2016.70.4189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。